SLC12A2 and Rett syndrome: In addition to the above study that demonstrated the beneficial effects of NKCC1-specific inhibitor bumetanide, commonly used clinically as a diuretic, it has been shown to be a useful treatment in mouse models of SZ (Kim et al., 2021), Down Syndrome (DS) (Deidda et al., 2015), Rett Syndrome (Banerjee et al., 2016), 22q11.2 deletion (DiGeorge) syndrome (Amin et al., 2017), neonatal epilepsy (Dzhala et al., 2005), and ID (Maset et al., 2021).